Fig. 2From: The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasmsThis schematic demonstrates the potential mechanisms of escape from JAK2 inhibition by ruxolitinib. (1) Ineffective JAK inhibition (2) Acquired tyrosine kinase domain mutation (3) Heterodimerization of JAK2 with JAK1 or TYK2 (4) Alternative signaling cascade activation (5) External cytokine effects (6) Epigentic mechanisms of transcriptional regulationBack to article page